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Summary: Staphylococci are still a leading cause of hospital infection. The 
success of nasal mupirocin for the control of epidemic methicillin-resistant 
Staphylococcus uureus (EMRSA), the prevention of colonization of central 
venous cannulae, and the prevention of septicaemia in haemodialysis patients 
should encourage the use of minimal dose regimens to minimize the emer- 
gence of mupirocin resistance. Mupirocin applied to the anterior nares 4- 
times daily usually eliminates S. aureus, including EMRSA, within 48 h. 
Elimination is sustained for several weeks in patients and staff. We recently 
found that a single dose, or a regimen of 4-times daily for 2 days, eliminated 
nasal carriage of S. aureus within 24 h; 7 days after a single dose, 92% of the 
subjects were still cleared; 7 days after the 2-day course, 96% remained free 
of nasal S. auras. Ward personnel who are nasal carriers of EMRSA can, 
provided that other carriage sites are negative, return to work after 2 days of a 
4-times daily intranasal regimen. The UK guidelines, recently published in 
this Journal, recommend an aggressive approach to identifying and eliminat- 
ing EMRSA, including the elimination of nasal carriage. This approach is 
increasingly associated with the control of EMRSA in the UK and elsewhere. 
Keywords: Mupirocin; nasal application; Staphylococcus aureus; coloniza- 
tion; eradication. 
Introduction 
Staphylococci continue to be a leading cause of hospital-acquired infection. 
There is increasing worldwide concern about the morbidity, mortality and 
cost of hospital outbreaks of strains of methicillin-resistant Staphylococcus 
aureus that have enhanced epidemicity (‘EMRSA’), and about 
coagulase-negative staphylococcal infection of implanted prosthetic 
devices. The anti-staphylococcal activity of mupirocin provides new 
opportunities to control and to prevent such infections, including the 
containment of EMRSA,14 the early colonization of central venous 
cannulae’ and the prevention of haemodialysis septicaemia6 and recurrent 
furunculosis. As with all antimicrobial agents, inappropriate or 
unnecessarily prolonged therapy with mupirocin may sooner, rather than 
later, result in the emergence of resistance and loss of efficacy. In view of the 
initial successes of mupirocin, it seems appropriate to review the evidence 
suggesting that relatively short-term therapy with the intranasal 
preparation (‘Bactroban Nasal’) may be effective, particularly in the context 
of the control of EMRSA. 
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Importance of nasal carriage as a source of infection with S. azzreus 
Although nasal carriage of S. aureu~ is usually harmless, it was shown more 
than 30 years ago that nasal carriers are more prone to surgical wound 
infection and in approximately half of these the infecting strain is derived 
from the patient’s own nose. 7,8 Other examples of auto-infection from nasal 
S. aureu~ include bacteraemia in haemodialysis patients6 and recurrent 
furunculosis. Nasal carriage of EMRSA can provide a source of EMRSA 
for the patient’s fingers (R. Wenzel, personal communication) and probably 
other skin sites and wounds.’ 
In addition to auto-infection, it was also shown in the 1960s that nasal 
carriage by patients and staff of strains of S. aureus with enhanced 
epidemicity (analogous to EMRSA) provided a significant source for nasal 
acquisition by other, previously non-colonized, patients.iOp” The early 
availability and use of intranasal mupirocin in the UK has been associated 
with the, hitherto unusual, successful control of EMRSA outbreaks by 
ourselves and by others.‘-’ 
Evidence for efficacy of short-term nasal mupirocin for elimination of 
nasal S. aureus 
From the outset in 1985, our published anecdotal observations on the first 
five patients and five nurses treated with a S-day course of intranasal 
mupirocin for the elimination of nasal EMRSA (all of whom had failed with 
10 days’ nasal application of 1% obstetric chlorhexidine) indicated that 
mupirocin was uniformly effective.i2 Chlorhexidine fails, despite the 
minimum inhibitory concentration (MIC) of 2.0 mg l-‘, probably because 
it is negatively charged and is inactivated by nasal secretions which carry the 
opposite polarity. Using a bioassay method we found no such inactivation of 
mupirocin by nasal secretions (Hill & Casewell, unpublished observations). 
Two parameters are important when assessing the efficacy of any regimen 
for clearing nasal carriage of S. aureus: the number of days therapy to 
achieve clearance and the post-treatment interval to recolonization. In a 
blind controlled trial, 2% mupirocin in soft white paraffin and lanolin given 
4-times a day to 32 healthy volunteers eliminated nasal S. aureus in all 
subjects within 2 days of a 5-day course.13 For all subjects, nasal S. uureus 
was eliminated for at least 2 weeks after the course, and even after 5 weeks 
only six (20%) had resumed carriage. Of those who ultimately resumed 
carriage, phage typing and antibiograms identified only 29% of subjects as 
having a relapse of colonization with the pre-treatment strain. None of these 
isolates showed an increase in the MIC of mupirocin. Soon after treatment 
the nasal flora was predominantly coagulase-negative staphylococci, 
coryneforms, or both. Minority populations of micrococci, Bacillus spp., 
Pseudomonas, Proteus or Escherichia coli also occurred but there was no 
overgrowth with mupirocin-resistant S. aureus or with yeasts or 
Gram-negative bacilli. The MICs of mupirocin for post-treatment 
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coagulase-negative staphylococci were always < 0.25 mg l-‘, an important 
observation as these organisms are a likely source of genetic elements that 
code for high-level mupirocin resistance in S. uureus.14 
A large hospital-wide outbreak of EMRSA in London in the early 1980s 
provided enough patients and staff with stable nasal colonization with 
EMRSA for us to confirm the efficacy of mupirocin against nasal EMRSA. 
Of 40 patients and 32 hospital staff, all but one patient and one staff member 
were cleared of nasal EMRSA within the first 48 h of a S-day course.’ 
Recolonization with EMRSA was uncommon and delayed: of the 40 
patients, 36 remained clear until discharge l-9 weeks later and four became 
recolonized 1-5 weeks after the course. Of the 32 staff, all were negative one 
week after the course and of the 22 still available for follow up 8 weeks after 
the course, all were consistently negative. 
These results for S. aureus, including EMRSA, suggested that 2, and 
certainly 3, days of mupirocin applied to the anterior nares four times a day 
is adequate to clear nasal carriage in all subjects. The exposure of S. aureus 
to mupirocin could be reduced still further by fewer applications per day or 
by reducing the number of days of treatment. We therefore conducted a 
blind controlled trial in which we compared the effect of a single dose of 
mupirocin with a regimen of 4-times daily for 2 days among 44 volunteers 
(mainly medical and nursing students) who had stable nasal carriage of 
methicillin-sensitive S. aureus. Figure 1 summarizes these results. The 
single dose was as effective as 4 doses at eliminating carriage in all subjects 
within the first 24 h. Seven days after the application of one dose and eight 
doses, 92% and 96% of the subjects, respectively, were still clear of nasal 
S. aureus. 
If these findings were true for EMRSA, hospital personnel with nasal 
EMRSA may be able to return to work 24 h after a single dose, but to 
sustain this clearance, 8 doses over 48 h will be required which, 7 days after 
the course, should ensure that 96% of them would still be negative. 
These findings will doubtless be relevant to those attempting elimination 
of nasal carriage in haemodialysis patients by giving mupirocin as an 
intermittent regimen.6 
The role of mupirocin in the control of EMRSA 
A revised version of the previous guidelines for the control of epidemic 
MRSA, drawn up by the Combined Working Party of the Hospital 
Infection Society and the British Society for Antimicrobial Chemotherapy, 
has been published recently in this Journal.15 These guidelines recommend 
the use of mupirocin for the successful control of EMRSA. The essential 
features of these guidelines are summarized as follows: 
1. Following the recognition of two or more patients with MRSA in a 
general ward, or one patient in a ward of high-risk patients (ICU etc.), there 
should be thorough and complete identification (by at least nasal screening) 
of all cases and carriers, including staff nasal carriers. 
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Figure 1. Effect of mupirocin on nasal carriage of Staphylococcus aureus. 
2. By typing with experimental phages, it is possible to determine 
whether the strain of MRSA is known to have enhanced epidemic potential, 
i.e. is ‘EMRSA’. In the UK this valuable information is provided by the 
Staphylococcal Reference Laboratory of the Public Health Laboratory 
Service at Colindale. 
3. An aggressive programme to eliminate all patient and staff carrier 
sites, to include the use of mupirocin to eliminate nasal carriage, should be 
initiated promptly. 
Our findings on the efficiency of short courses described below should 
help hospital infection control personnel rationalize the minimal dose 
regimens of mupirocin for clearance of nasal carriage and indicate the 
timing of subsequent follow-up nasal swabs that are required to check the 
continued clearance of treated carriers. 
Newly identified staff nasal carriers should have other sites (skin lesions, 
throat, axillae and perineum) screened for MRSA and they should then start 
nasal mupirocin 4-times daily for 5 days and be taken off duty. Provided 
that these other sites are negative, they can return to work after only 48 h 
with the certainty of cleared nasal carriage. This regimen will ensure nasal 
clearance for at least 7-14 days after the course” and re-screening for 
recolonization of the nose with MRSA need only be carried out weekly. 
This regimen carries significant cost savings in terms of lost working days. 
At King’s College Hospital, with the early availability of mupirocin, we 
have, since 1985, adopted these principlesI with some success. Table I 
Mupirocin dosing and MRSA 
Table I. Epidemic MRSA ( ‘EMRSA-1’ ) 
in a liver transplant unit 
No. No. 
index secondary 
Year cases cases* 
198.5 
1986 
: 1 
4 
1987 
1988 
it 0 
9 2 : 
Total 6 9 
* All colonization, no infections. 
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shows, as an example, the repeated introduction of a strain of MRSA of 
known epidemic and pathogenic potential (‘EMRSA-1’) into a ward of 
highly immunocompromised liver-transplant patients. There have, to date, 
been only nine secondary transmissions and all have been recognized and 
contained before colonization became clinical infection. Others are also now 
reporting similar success by using mupirocin in this way. *W Early 
recognition and definition of outbreaks and an aggressive approach to 
elimination of the organism is, even in countries where mupirocin is 
unavailable and not used, also meeting with some success, albeit with more 
difficulty.17 
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